Understand the source comparison
Best Peptides for Bulging Disc: Research Protocol Comparison
BPC-157 VEGF upregulation, angiogenesis in avascular disc tissue, type I collagen synthesis 250–500 mcg daily (7–10 mcg/kg) subcutaneous 8–12 weeks minimum Rodent models published; human trials limited to case reports Strongest mechanistic rationale for annulu
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, angiogenesis in avascular disc tissue, type I collagen synthesis
- 250–500 mcg daily (7–10 mcg/kg) subcutaneous
- 8–12 weeks minimum
- Rodent models published; human trials limited to case reports
- Strongest mechanistic rationale for annulus fibrosus repair; best suited for radial tear pathology
- TB-500
- Actin polymerization, cell migration, TGF-β downregulation, organized collagen alignment
- 2–5 mg twice weekly (35–70 mcg/kg) subcutaneous
- 4–6 weeks loading, then maintenance
- Cardiac and tendon models; no disc-specific human trials
- Most effective for remodeling phase; reduces fibrosis and improves collagen organization
- GHK-Cu
- MMP-1 inhibition, TIMP upregulation, dual anti-catabolic and anabolic collagen effect
- 1–3 mg daily (15–40 mcg/kg) subcutaneous
- 12–16 weeks for degenerative models
- Dermal wound healing studies; limited musculoskeletal data
- Best for chronic degeneration where halting collagen loss is as critical as promoting synthesis
- Thymosin Alpha-1
- Immune modulation, cytokine regulation, non-specific anti-inflammatory
- 1.6–3.2 mg twice weekly subcutaneous
- 8 weeks typical
- Autoimmune and viral models; no disc-specific research
- Weak rationale for structural disc repair; may reduce pain without addressing pathology
- Ipamorelin + CJC-1295
- Growth hormone secretagogue, systemic IGF-1 elevation
- 200–300 mcg daily (peptide blend)
- 12+ weeks for systemic effects
- General tissue repair models; no disc-specific mechanistic evidence
- Indirect benefit through systemic GH/IGF-1; insufficient for localized disc pathology